Rhythm Pharmaceuticals Inc

Research Rhythm Pharmaceuticals Inc (RYTM) on Bullrun: market cap USD 7.55B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRYTM
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 7.55B
• Financial periodFY2025
• RevenueUSD 189.76M
• Revenue growth45.8%
• Net income-USD 196.54K
• Free cash flow-USD 116.63M
• Gross margin89.7%

Valuation Snapshot

latest market cap is USD 7.55B.

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.

Frequently asked questions

What is Rhythm Pharmaceuticals Inc's market cap?

Rhythm Pharmaceuticals Inc's market capitalization is USD 7.55B.

What does Rhythm Pharmaceuticals Inc do?

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.